ADJUVANT CHEMOTHERAPY (TRIETHYLENE THIOPHOSPHORAMIDE) WITH RADICAL MASTECTOMY AND RADIOTHERAPY IN BREAST CANCER

Area of Science:

• Oncology
• Surgical Oncology
• Radiotherapy

Background:

• Adjuvant chemotherapy with triethylene thiophosphoramide (Thio-TEPA) shows promise in reducing breast cancer recurrence after mastectomy.
• Concerns exist regarding the safety of combining Thio-TEPA, a radiomimetic agent, with postoperative radiotherapy due to potential additive toxic effects.

Purpose of the Study:

• To evaluate the safety and efficacy of administering triethylene thiophosphoramide (Thio-TEPA) concurrently with radical mastectomy and postoperative radiotherapy in breast cancer patients.
• To address fears of serious complications arising from the combined use of Thio-TEPA and radiotherapy.

Main Methods:

• A cohort of 70 patients with breast cancer underwent radical mastectomy followed by administration of triethylene thiophosphoramide (Thio-TEPA).
• The majority of these patients also received postoperative radiotherapy.

Main Results:

• The study demonstrated that triethylene thiophosphoramide (Thio-TEPA) can be safely given to breast cancer patients undergoing radical mastectomy and adjuvant radiotherapy.
• No significant increase in serious complications was observed due to the combined treatment regimen.

Conclusions:

• Adjuvant chemotherapy with triethylene thiophosphoramide (Thio-TEPA) is a safe and beneficial option for breast cancer patients planned for radical mastectomy and postoperative radiotherapy.
• The benefits of Thio-TEPA in reducing tumor recurrence should not be withheld due to concerns about combined radiotherapy use.